Intrahepatic Cholangiocarcinoma Clinical Trial
Official title:
Duvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk, Phase II, Single Center, Randomized Controlled Study
Verified date | January 2023 |
Source | Tianjin Medical University Cancer Institute and Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
Status | Recruiting |
Enrollment | 70 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age = 18, male or female; 2. Pathological diagnosis confirmed intrahepatic cholangiocarcinoma, which could be resected surgically; One of the following conditions shall be met: 2.1 Single tumor, diameter greater than 5cm (T1b) 2.2 Single tumor with vascular invasion (T2), multiple tumors = 3 2.3 Tumor penetrating visceral peritoneum (T3) or directly invading surrounding organs (T4) 2.4 Suspicious lymph node metastasis in Zone 8, 12 or 13 3. Can not received systemic treatment before participating in the study; 4. ECOG PS score 0-1; 5. The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immune deficiency diseases. 6. Laboratory inspection shall meet the following requirements: Women of childbearing age must have a negative pregnancy test (serum or urine) within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug; For men, they should be surgically sterilized or agree to use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug. 7. The patient voluntarily participated and signed the informed consent form; 8. It is expected that the compliance is good, and the efficacy and adverse reactions can be followed up according to the requirements of the scheme. Exclusion Criteria: 1. Patients who received PD-1, PD-L1, PD-L2, CTLA-4 before enrollment, or directly received another stimulatory or co inhibitory T cell receptor (such as CTLA-4, 0X40, CD137); 2. Any other research drugs within 4 weeks before enrollment; 3. Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy); 4. Congenital or acquired immune function defects, such as human immunodeficiency virus (HIV) infection; 5. Uncontrollable clinical cardiac symptoms or diseases, such as NYHA II and above heart failure unstable angina pectoris, myocardial infarction within one year, and clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention; 6. Severe infection (such as intravenous drip of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first drug administration, or fever of unknown cause>38.5 ° C occurred during screening/before the first drug administration; 7. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 8. Live attenuated vaccine shall be inoculated within 4 weeks before the first administration or planned during the study period; 9. Suffered from or accompanied by other system malignant tumors in the last 5 years (except cured skin basal cell carcinoma, cervical carcinoma in situ and ovarian cancer); 10. Allergic to any test drug; 11. Pregnant and lactating women, fertile subjects are unwilling to take effective contraceptive measures; 12. Uncontrollable psychosis; 13. Other situations that the researcher thinks are not suitable for inclusion. If the patient has central nervous system metastasis, has serious laboratory examination abnormalities, and is accompanied by family or social factors, it will affect the safety of the subject, or the collection of data and samples. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1-year relapse free survival rate | 1-year | ||
Secondary | 2-year relapse free survival rate | 2-year | ||
Secondary | ORR | 1-year | ||
Secondary | DCR | 1-year | ||
Secondary | R0 resection rate | 1-year | ||
Secondary | 30 day postoperative complication rate | 30 day | ||
Secondary | Occurrence of adverse reactions | 1-year | ||
Secondary | 1-year OS | 1-year | ||
Secondary | 2-year OS | 2-year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Completed |
NCT01938729 -
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
|
Phase 1 | |
Completed |
NCT03230318 -
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT06239532 -
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05535647 -
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT02254681 -
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
|
Phase 2 | |
Active, not recruiting |
NCT01954745 -
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
|
Phase 2 | |
Completed |
NCT01347333 -
Stereotactic Body Radiotherapy for Liver Tumors
|
N/A | |
Active, not recruiting |
NCT04526106 -
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05285358 -
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
|
Phase 1 | |
Completed |
NCT03320980 -
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
|
N/A | |
Withdrawn |
NCT05019677 -
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
|
Phase 2 | |
Withdrawn |
NCT03801499 -
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT05489692 -
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
|
||
Recruiting |
NCT06101277 -
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
|
N/A | |
Active, not recruiting |
NCT01917370 -
VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
|
N/A | |
Withdrawn |
NCT01775280 -
Response of Hepatic Tumors to Radioembolization
|
Phase 2 | |
Not yet recruiting |
NCT05342194 -
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
|
Phase 3 |